PICOSSIDE (0.4.1)
Approved for use through 07/13/2006 (0.40) 054-030.

U.S. Peletra att (1/sekmaik Office, U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of infamination unless of contains a volution contain named to

Application Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)					Date							
					lamed I	nventor	Take	shi YAMAMOTO				
					iit							
					iner Na	me						
				Attorn	ey Doc	ket Numb	er	70404.108/ha				
					U.S.I	PATENTS				Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	Issue Date Name of Patentee or Applicant				Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1											
If you wis	h to a	dd additional U.S. Pater	nt citation	n inform	ation pl	ease click	the A	dd button.		Add		
			U.S.P	ATENT.	APPLI	CATION P	UBLI	CATIONS		Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant Rele			Releva	es,Columns,Lines where want Passages or Relevant res Appear		
	1	20030007227	A1	2003-01	2003-01-09 Ogmo							
	2	20020075136	A1	2002-06-20		Nakaji et al.						
If you wish to add additional U.S. Published Application citation information please click the Add button. Add												
				FOREIG	SN PAT	ENT DOC	UME	NTS		Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Publicatio Date	n	lame of Patentee or pplicant of cited locument		Pages,Colum where Releva Passages or F	nt Relevant	Тs

					Figures Appear		П
1	11-281375	JP	A	1999-10-15		V	
2	11-120491	JP	A	1999-04-30		V	

Application Number Filing Date INFORMATION DISCLOSURE First Named Inventor Takeshi YAMAMOTO STATEMENT BY APPLICANT Art I Init (Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number 70404 108/ha

Г				NON-PATER	NT LITE	RATURE DO	CUMENTS	Remove		
I	If you wish to add additional Foreign Patent Document citation information please click the Add button Add									
		6	1 136 977	EP	A2	2001-09-26				
		5	06-195056	JP	A	1994-07-15				Z
		4	2002-166787	JP	A	2002-06-11				Z
		3	01-188178	JP	A	1989-07-27				V

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Examiner Cite Т5 (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), Initials* No publisher, city and/or country where published. International Search Report issued in the corresponding International Application No. PCT/JP2005/002684, mailed on 7 May 31, 2005.

If you wish to add additional non-patent literature document citation information please click the Add button Add F

EXAMINER SIGNATUR

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. 2 Enter office that issued the document, by the two-letter code (WIPO Standard ST 3). 3 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the senal number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible. Applicant is to place a check mark here if English language translation is attached.

Examiner Signature

Application Number Filing Date Filing Date

CERTIFICATION STATEMENT

Please see	37	CER	1 97	and	1 02	to	make the	annro	nriata	colort	inn/	e٧

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 3.7 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(s)(s).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- 7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Torri or the signature.			
Signature	/Joseph R. Keating #37,368/	Date (YYYY-MM-DD)	2006-08-17
Name/Print	Joseph R. Keating	Registration Number	37368

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant Affice, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.